PTPRC and neoplasm: Fig 4C shows that COMBO treatment induced a higher CD45+ leukocyte recruitment compared with vehicle, which was mainly constituted by F4/80+ tumor‐associated macrophages (TAMs) and CD11c+MHCII+ dendritic cells (DC) (Fig 4D).